Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

Overview of attention for article published in OncoTargets and therapy, August 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter: 2 X users
patent: 1 patent

reddit: 1 Redditor

Citations

dimensions_citation: 47 Dimensions

Readers on

mendeley: 45 Mendeley

Summary X Patents Reddit Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1

Application WO-2020069118-A1

World Intellectual Property Organisation (WIPO)